Alembic Pharma Q1 profit rises 12.1% to ₹173 crore as US formulations surge
Alembic Pharmaceuticals reported Q1 FY27 revenue from operations of ₹2,149.77 crore, up from ₹1,710.72 crore a year earlier. India branded revenue grew 7% to ₹642 crore, while US formulations rose 49% to ₹778 crore.
Alembic Pharmaceuticals reported Q1 FY27 net profit of ₹173.07 crore, up 12.1% year-on-year, supported by broad-based growth. Its India branded business rose 7% to ₹642 crore, while US formulations increased 49% to ₹778 crore.
Why this matters
No related recent Alembic Pharmaceuticals signals were provided. The Q1 FY27 result shows US formulations outpacing India branded revenue growth.
Retail-company signals are accelerating, up 202957% QoQ.